[2-Br-alpha-ergocryptine in the treatment of amenorrhea-galactorrhea syndromes and in inhibition of puerperal lactation. Effect on secretion of prolactin and pituitary gonadotropin].
D000328:Adult; D000568:Amenorrhea / Q000188:drug therapy*; D004873:Ergolines / Q000627:therapeutic use*; D005260:Female; D005687:Galactorrhea / Q000188:drug therapy*; D006065:Gonadotropins, Pituitary / Q000378:metabolism*; D006801:Humans; D007774:Lactation / Q000187:drug effects*; D007775:Lactation Disorders / Q000188:drug therapy*; D010902:Pituitary Gland / Q000378:metabolism*; D010903:Pituitary Gland, Anterior / Q000378:metabolism*; D011247:Pregnancy; D011388:Prolactin / Q000378:metabolism*; D011644:Puerperal Disorders / Q000188:drug therapy*
D004873:Ergolines; D006065:Gonadotropins, Pituitary; D011388:Prolactin
La 2-Br-alpha-ergocriptina nel trattamento delle sindromi di amenorrea-galattorrea e nella inibizione della lattazione puerperale. Effetto sulla secrezione prolattinica e gonadotropa ipofisaria